Michael Dixon has over 20 years of experience working in an executive role for venture-backed companies including CFO of GeminX Pharmaceuticals which was acquired by Cephalon in 2011. More recently, Mr Dixon has been CFO or acting CFO for other venture backed pharmaceutical companies including DalCor Pharmaceuticals.
During his tenure as Chief Financial Officer of Gemin X Pharmaceuticals, he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada. Mr. Dixon was Interim COO and vice president of finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.

• 

  CFO: Chief Financial Officer in Kisoji

  Breakthrough antibody discovery for breakthrough therapeutics

• 

  Principal in Sanderling Ventures

  Dedicated to early-stage biomedical financing and active management